Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.

Aso Y, Takada Y, Tomotsune K, Chiba Y, Matsumura M, Jojima T, Sato M, Fujita N, Kuroda H, Murano S, Usui I

International journal of clinical practice9 Nov 2020Cited by 6 (Europe PMC)

PMID33099848DOI10.1111/ijcp.13734PepBankPUB-33099848

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes inadequately controlled on insulin, HbA1c fell by 0.7% with once-daily insulin degludec plus liraglutide and by 0.3% with twice-daily IDegAsp; the conclusion reports no significant difference in glycaemic control.
In plain wordsIn adults with type 2 diabetes, HbA1c fell 0.7% on degludec plus liraglutide and 0.3% on IDegAsp; the authors found no significant difference.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change over 52 weeks
Study
n = 52
Comparator
Twice-daily insulin degludec/insulin aspart co-formulation (IDegAsp)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c decrease
0.7%
IDeg + Lira
HbA1c decrease
0.3%
IDegAsp
Source sentences
Summary
After 52 weeks, HbA1c decreased by 0.3% in the IDegAsp group and by 0.7% in the IDeg + Lira group. The HbA1c reduction was greater in the IDeg + Lira group than in the IDegAsp group.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients were randomly allocated at a 1:1 ratio to receive either the once-daily dual injection of IDeg + Lira (n = 24) or twice-daily single injection of IDegAsp (n = 28).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3309984801
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes inadequately controlled on insulin, 40% on insulin degludec plus liraglutide versus 19% on IDegAsp reached HbA1c below 7.0%.
In plain wordsIn adults with type 2 diabetes, 40% reached HbA1c below 7.0% on degludec plus liraglutide and 19% on IDegAsp; no significant glycaemic difference.
Peptide
Liraglutide
Outcome
IncreasePatients achieving HbA1c below 7.0%
Study
n = 52
Comparator
Twice-daily insulin degludec/insulin aspart co-formulation (IDegAsp)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c <7.0% achieved
40%
IDeg + Lira
HbA1c <7.0% achieved
19%
IDegAsp
Source sentences
Summary
19% of patients on IDegAsp versus 40% on IDeg + Lira achieved HbA1c < 7.0%.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients were randomly allocated at a 1:1 ratio to receive either the once-daily dual injection of IDeg + Lira (n = 24) or twice-daily single injection of IDegAsp (n = 28).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3309984802
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes inadequately controlled on insulin, pre-breakfast and pre-dinner blood glucose at 52 weeks was significantly lower with insulin degludec plus liraglutide than with IDegAsp.
In plain wordsIn adults with type 2 diabetes, blood glucose before breakfast and dinner was lower on insulin degludec plus liraglutide than on IDegAsp.
Peptide
Liraglutide
Outcome
DecreasePre-breakfast and pre-dinner blood glucose at 52 weeks
Study
n = 52
Comparator
Twice-daily insulin degludec/insulin aspart co-formulation (IDegAsp)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Pre-breakfast and pre-dinner blood glucose at 52 weeks were significantly lower in the IDeg + Lira group than in the IDegAsp group.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients were randomly allocated at a 1:1 ratio to receive either the once-daily dual injection of IDeg + Lira (n = 24) or twice-daily single injection of IDegAsp (n = 28).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3309984803
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes inadequately controlled on insulin, BMI fell more with insulin degludec plus liraglutide than with IDegAsp.
In plain wordsIn adults with type 2 diabetes, BMI fell more on insulin degludec plus liraglutide than on IDegAsp.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction
Study
n = 52
Comparator
Twice-daily insulin degludec/insulin aspart co-formulation (IDegAsp)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The reduction in body mass index (BMI) was greater in the IDeg + Lira group than in the IDegAsp group throughout the study period.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients were randomly allocated at a 1:1 ratio to receive either the once-daily dual injection of IDeg + Lira (n = 24) or twice-daily single injection of IDegAsp (n = 28).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3309984804
05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes inadequately controlled on insulin, confirmed hypoglycaemia rates were 0.69 per patient-year with insulin degludec plus liraglutide and 1.32 with IDegAsp.
In plain wordsIn adults with type 2 diabetes, low blood sugar events were 0.69 per patient-year on insulin degludec plus liraglutide and 1.32 on IDegAsp.
Peptide
Liraglutide
Outcome
Not applicableConfirmed hypoglycaemia rate
Study
n = 52
Comparator
Twice-daily insulin degludec/insulin aspart co-formulation (IDegAsp)
Outcome group
Adverse events · Whole body
Measurements
confirmed hypoglycaemia rate
1.32 per patient/year
IDegAsp
confirmed hypoglycaemia rate
0.69 per patient/year
IDeg + Lira
Source sentences
Summary
The confirmed hypoglycaemia rates were 1.32 and 0.69 per patient/year of exposure to IDegAsp and IDeg + Lira, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients were randomly allocated at a 1:1 ratio to receive either the once-daily dual injection of IDeg + Lira (n = 24) or twice-daily single injection of IDegAsp (n = 28).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3309984805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.